In addition, the diagnosis and therapy of gene fusions including ALK and ROS1 were revolutionary for TKI therapy in NSCLC, demonstrating remarkable antitumor effects (4–6). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.